Business Wire

ADVA

15.12.2020 09:02:11 CET | Business Wire | Press release

Share
ADVA launches new generation of edge and access clocks for 5G network timing

ADVA (FSE: ADV) today launched a unique set of edge and access network synchronization devices with enhanced capabilities for next-generation applications such as 5G. The latest Oscilloquartz solutions address key challenges for a wide range of industries by bringing new levels of timing accuracy and resilience to edge networks. The OSA 5412 and 5422 offer precise phase, frequency and time-of-day synchronization and can be used for time-as-a-service applications. For the first time, communication service providers, enterprises, broadcast networks and power utilities can deploy synchronization technology at the edge that features multi-band GNSS receivers for nanosecond accuracy. The OSA 5412 and 5422 utilize in-service sync probing and assurance as well as innovative GNSS assurance capabilities. The products also provide support for eight field-upgradeable 10Gbit/s ports, ensuring the scale and efficiency needed for next-generation smart grids, industrial IoT applications and 5G connectivity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215005081/en/

“Our latest solutions build on the great success we’ve had with our access synchronization product line. Now operators can harness the power of multi-band GNSS receivers to deliver highly accurate, UTC-traceable timing at the network edge. That enables the availability and precision that will be essential for tomorrow’s services,” said Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. “By extending the feature set of our edge technology, we’re empowering CSPs to smoothly transition to the reliability and accuracy required for 5G and, at the same time, enabling our unique innovation to be used across a wide range of verticals. With support for 10Gbit/s and 1Gbit/s interfaces as well as hardware timestamping, our access timing products are the ultimate in future-proof, space-efficient synchronization.”

The OSA 5412 is a highly flexible access network synchronization solution that offers compact and cost-effective timing distribution and assurance. The OSA 5422 is engineered for the most extreme conditions. It meets stringent frequency and phase synchronization requirements, delivers the best holdover performance of any edge device on the market, and supports multiple legacy interfaces such BITS and IRIG. Both solutions address new ITU-T specifications, including for class A and B PRTCs, ePRTCs with strict holdover requirements, and the newly improved class C and D boundary clocks. They also feature onboard multi-band, multi-constellation GNSS receivers that overcome ionospheric delay variation far more cost-efficiently than rival solutions using high-end rubidium oscillators. The OSA 5412 and 5422 support multiple PTP profiles, NTP and SyncE with the highest number of 1/10GbE ports on the market. What’s more, both devices are engineered with optional OLED display and with hot-swappable modules and power supplies to be easily upgraded in the field.

“Access grandmaster clocks need to meet stricter demands for accuracy and reliability than ever before, and many industries have their own specific set of stringent timing requirements. That’s why we’ve evolved our portfolio of edge and access network synchronization solutions for the specific challenges of the 5G era,” commented Gil Biran, general manager, Oscilloquartz, ADVA. “Our OSA 5412 and 5422 answer the most urgent timing needs of mission-critical infrastructure in multiple verticals. They provide nanosecond precision, an abundance of fan-out interface options and operational simplicity thanks to the management and monitoring capabilities of our Ensemble Controller with Sync Director. Operators of broadcast, healthcare, financial networks and more now have a straightforward and affordable path from legacy to next-generation timing.”

Further information on the OSA 5412 and 5422 is available in these slides: https://adva.li/osa-5412-5422-slides .

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz

Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com .

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release

The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release

Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye